This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus,  summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies. weiterlesen